| 000 | 01281 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250515033114.0 | ||
| 264 | 0 | _c20060829 | |
| 008 | 200608s 0 0 eng d | ||
| 022 | _a1198-743X | ||
| 024 | 7 |
_a10.1111/j.1469-0691.2006.01528.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPower, E | |
| 245 | 0 | 0 |
_aImpact of antibiotic restrictions: the pharmaceutical perspective. _h[electronic resource] |
| 260 |
_bClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases _cAug 2006 |
||
| 300 |
_a25-34 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDrug Industry _xeconomics |
| 650 | 0 | 4 | _aDrug Resistance, Bacterial |
| 650 | 0 | 4 |
_aFamily Practice _xstatistics & numerical data |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPractice Patterns, Physicians' |
| 650 | 0 | 4 |
_aResearch _xeconomics |
| 773 | 0 |
_tClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases _gvol. 12 Suppl 5 _gp. 25-34 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1469-0691.2006.01528.x _zAvailable from publisher's website |
| 999 |
_c16419477 _d16419477 |
||